Tempus AI

We are collaborating with OneOncology, the fastest-growing national platform for independent oncology practices, to broaden patient access to cutting-edge clinical trials. As part of the collaboration, we’re combining the power of our TIME Trial® Program with OneOncology’s robust research infrastructure and large national network of oncology practice partners to bring more biomarker-driven trials to patients in the community setting. Learn more: https://tempus.co/3U41Npy

Our science and medical teams are gathering in-person in our Chicago office for #Innovate2024. This time is being used to align and strategize on the future of Tempus' offerings across the business. Some highlights from the day include: ▪️A fireside chat with Amy Abernethy of Highlander Health  on the future of healthcare ▪️Sessions on emerging trends in Genomics, Clinical Oncology, Cardio, Neuro, Drug Development, and AI-Enabled Diagnostics ▪️A keynote address from Jamie Metzl ▪️ A "State of the Union" by our CEO Eric Lefkofsky

We’re excited to announce a collaboration with JW Pharmaceutical Corporation to leverage both real-world data (RWD) and biological modeling to support efficient hypothesis generation and rapid validation in early therapeutic research in oncology. JW Pharma is now tapping into our rich multimodal dataset and extensive repository of organoid models to accelerate its efforts in multiple indications. Learn more: https://tempus.co/3YigJlk

As #BreastCancerAwarenessMonth comes to a close, we’re reflecting on the hundreds of thousands of patients who receive a breast cancer diagnosis each year and the importance of advancing personalized care. Our liquid biopsy panel, xF+, can uncover important acquired mutations like ESR1 and PIK3CA – which studies show are highly prevalent in mBC patients. Identifying patients with these biomarkers are pivotal in expanding treatment options and improving patient care. Read more: https://tempus.co/3BZ0e6j

Cleveland Clinic utilized the Tempus TIME program to assess the effectiveness of AI in patient screening, matching, and enrollment processes for #clinicaltrials. The program successfully facilitated large-scale patient screening and matching, improving patient access and enrollment with an average of more than one consent per day over six months. AI-enhanced patient matching plays a pivotal role in maximaxing trial outcomes. These elements are fundamental to the TIME program. Learn more in the full case study here: https://tempus.co/3NARyFz

Avacta and Tempus AI Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology. https://lnkd.in/ewzvjFSQ

In a recent webinar, Michelle Mack, PhD, led a lively discussion with Scott Boiko from Nimbus Therapeutics and Richard Klinghoffer, PhD on advancing drug development using Tempus' comprehensive 3D patient-derived organoid (PDO) biorepository and our real-world data (RWD) platform. Access the full recording here: https://tempus.co/3U7Vhht

After a quarter century as a serial entrepreneur, Eric Lefkofsky wants his latest unicorn, health tech firm Tempus AI, to be the “enduring legacy” of his career. Here’s how he hopes it will dramatically change millions of patients’ lives. https://lnkd.in/ePaTrxK9

It's not too late to register for tomorrow's webinar, "Precision pathways: Insights and strategies to navigate regulatory requirements for oncology diagnostics" with Hakan Sakul, PhD, Elaine Katrivanos and Lauren Silvis. These industry experts will be discussing how to approach FDA regulatory requirements, offering insights to guide diagnostic development and enhance precision medicine initiatives. Register here: https://tempus.co/3YbCFOS

October is #BreastCancerAwarenessMonth, a time to highlight the importance of early detection and personalized care. As one of the most prevalent cancers worldwide, breast cancer demands precise, cutting-edge diagnostics for optimal care. Tempus offers streamlined molecular testing across every stage of the cancer continuum, providing insights needed to tailor treatment plans for patients. Explore our comprehensive testing solutions that can help support breast cancer patient care: https://tempus.co/4f6Pn8J